Other languages Indaptus Therapeutics, Inc.

Equities

INDP

US45339J1051

Market Closed - Nasdaq Other stock markets 03:59:51 2024-05-14 pm EDT			5-day change	1st Jan Change
2.13 ^USD	+0.47%		+3.90%	+21.02%

May. 08	Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 14	Top Premarket Gainers	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Top Premarket Gainers	Mar. 14
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13
Top Midday Gainers	Mar. 04
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial	Mar. 04
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels	Feb. 08
Indaptus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06
Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20	Nov. 06
Indaptus Therapeutics, Inc. Releases Interim Data from the First Cohort of Four Patients in its Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20	23-10-31
Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20	23-09-19
Indaptus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20	23-08-10
Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023	23-08-08
Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Indaptus Therapeutics, Inc. Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at American Association for Cancer Research Conference 2023	23-04-19
Indaptus Therapeutics, Inc. Announces Executive Changes	23-03-23
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-17
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-17
Indaptus Therapeutics, Inc. Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors	23-03-13
Indaptus Therapeutics, Inc. Doses First Subject in Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors	23-03-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Indaptus Therapeutics, Inc.

Equities

INDP

US45339J1051

Other languages

Filters